Evidence map›Paper›PMID 27296507›Full record

ArticleCirculation research2016

Radiofrequency Renal Denervation Protects the Ischemic Heart via Inhibition of GRK2 and Increased Nitric Oxide Signaling.

David J Polhemus, Juan Gao, Amy L Scarborough, Rishi Trivedi, Kathleen H McDonough, Traci T Goodchild, Frank Smart, Daniel R Kapusta, David J Lefer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Renal interoception in health and disease.Autonomic neuroscience : basic & clinical · 2024
    Review
  6. Effects of renal denervation on the incidence and severity of cardiovascular diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  7. The roles of G protein-coupled receptor kinase 2 in renal diseases.Journal of cellular and molecular medicine · 2024
    Review
  8. Article
  9. Article
  10. Celiac ganglia neurolysis suppresses high blood pressure in rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction.Clinical research in cardiology : official journal of the German Cardiac Society · 2021
    Article
  17. Renal Denervation to Treat Heart Failure.Annual review of physiology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

David J PolhemusFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Juan GaoFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Amy L ScarboroughFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Rishi TrivediFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Kathleen H McDonoughFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Traci T GoodchildFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Frank SmartFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.).
Daniel R KapustaFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.). dlefe1@lsuhsc.edu Dkapus@lsuhsc.edu.
David J LeferFrom the Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., A.L.S., R.T., T.T.G., F.S., D.R.K., D.J.L.); Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA (D.J.P., J.G., R.T., T.T.G., D.R.K., D.J.L.); and Department of Physiology, LSU Health Sciences Center, New Orleans, LA (K.H.M.). dlefe1@lsuhsc.edu Dkapus@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · US

Funding

Preclinical Consortium to Facilitate Translation of Cardioprotective TherapiesU24HL094373 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2010 to 2014
$9.6M
Functional Cardio-MetabolomicsP20HL113452 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2012 to 2016
$4.8M
Cardioprotective Actions of Hydrogen SulfideR01HL092141 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2013
$1.9M
Novel Sulfide Releasing Agents for Ischemic InjuryR01HL116571 · NHLBI · WASHINGTON STATE UNIVERSITY · PI LEFER, DAVID JOSEPH, XIAN, MING · 2014 to 2017
$1.8M
Nitrite Mediated CardioprotectionR01HL093579 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2012
$1.5M
NHLBI NIH HHS P20 HL113452NHLBI NIH HHS R01 HL092141NHLBI NIH HHS R01 HL093579NHLBI NIH HHS R01 HL116571NHLBI NIH HHS U24 HL094373
6 · The paper itself

Abstract

rationaleCatheter-based renal denervation (RDN) is currently under development for the treatment of resistant hypertension and is thought to reduce blood pressure via interruption of sympathetic pathways that modulate cardiovascular function. The sympathetic nervous system also plays a critical role in the pathogenesis of acute myocardial infarction and heart failure.

objectiveWe examined whether treatment with radiofrequency (RF)-RDN would protect the heart against subsequent myocardial ischemia/reperfusion injury via direct effects on the myocardium. METHODS AND

resultsSpontaneously hypertensive rats received either bilateral RF-RDN or sham-RDN. At 4 weeks after RF-RDN (n=14) or sham-RDN (n=14) treatment, spontaneously hypertensive rats were subjected to 30 minutes of transient coronary artery occlusion and 24 hours -7 days reperfusion. Four weeks after RF-RDN, myocardial oxidative stress was markedly attenuated, and transcription and translation of antioxidants, superoxide dismutase 1 and glutathione peroxidase-1, were significantly upregulated compared with sham-RDN spontaneously hypertensive rats. RF-RDN also inhibited myocardial G protein-coupled receptor kinase 2 pathological signaling and enhanced myocardial endothelial nitric oxide synthase function and nitric oxide signaling. RF-RDN therapy resulted in a significant reduction in myocardial infarct size per area at risk compared with sham-RDN (26.8 versus 43.9%; P<0.01) at 24 hours postreperfusion and significantly improved left ventricular function at 7 days after myocardial ischemia/reperfusion.

conclusionsRF-RDN reduced oxidative stress, inhibited G protein-coupled receptor kinase 2 signaling, increased nitric oxide bioavailability, and ameliorated myocardial reperfusion injury in the setting of severe hypertension. These findings provide new insights into the remote cardioprotective effects of RF-RDN acting directly on cardiac myocytes to attenuate cell death and protect against ischemic injury.

Indexed as

AnimalsCatheter AblationDenervationG-Protein-Coupled Receptor Kinase 2KidneyMaleMyocardial IschemiaMyocardial Reperfusion InjuryNitric OxideOxidative StressRatsRats, Inbred SHRRats, Inbred WKYSignal TransductionG-Protein-Coupled Receptor Kinase 2Grk2 protein, ratNitric OxideG protein-coupled receptor kinasesnervous systemnitric oxideoxidative stressradiofrequencyrenal denervationsympathetic

Identifiers

PMID27296507
PMCPMC4959827
OpenAlexW2443251917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.